Source: International Congress 2015 – Treatment of IPF
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vincent Cottin (Lyon, France), Vincent Cottin, Toby M. Maher, Arata Azuma, Lesley Groves, Philip Hormel, Magnus Sköld, Sara Tomassetti, Dirk Koschel. Pirfenidone post-authorization safety registry (PASSPORT) update. Eur Respir J 2015; 46: Suppl. 59, 4500

Member's Comments

No comment yet.

Related content which might interest you: Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014